NIKKEI 225
38,719.35 -227.58 (-0.58%) HANG SENG
19,233.55 +12.93 (+0.07%) CRUDE OIL
79.06 -0.20 (-0.25%) GOLD FUTURES
2,422.50 -3.40 (-0.14%) DOW
39,872.99 +66.22 (+0.17%) Bitcoin GBP
54,997.40 -1,026.30 (-1.83%)
NewAmsterdam Pharma Company N.V. (NAMS)
After hours:
| Previous close | 19.84 |
| Open | 19.59 |
| Bid | 19.35 x 400 |
| Ask | 19.52 x 400 |
| Day's range | 19.01 - 20.21 |
| 52-week range | 5.63 - 26.35 |
| Volume | |
| Avg. volume | 184,253 |
| Market cap | 1.753B |
| Beta (5Y monthly) | 0.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.70 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 34.71 |
Globe NewswireNewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
-- Presentations include new data from OCEAN, ROSE, and ROSE2 Phase 2 clinical trials, demonstrating obicetrapib’s impact on key lipid and lipoprotein biomarkers -- -- On track to report topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and Phase 3 BROADWAY trial in ASCVD in 4Q 2024 -- NAARDEN, the Netherlands and MIAMI, May 21, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company d
Simply Wall St.NewAmsterdam Pharma First Quarter 2024 Earnings: US$1.06 loss per share (vs US$0.50 loss in 1Q 2023)
NewAmsterdam Pharma ( NASDAQ:NAMS ) First Quarter 2024 Results Key Financial Results Net loss: US$93.8m (loss widened...
- Globe Newswire
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
-- Enrolled over 9,500 patients in Phase 3 PREVAIL global CVOT-- -- On-track to report topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and Phase 3 BROADWAY trial in ASCVD in 4Q 2024 -- -- Dosed first patients in TANDEM, pivotal Phase 3 trial evaluating fixed-dose combination of obicetrapib and ezetimibe; topline data expected in 1Q 2025 -- -- Company to host R&D event on May 16, 2024, beginning at 9:00 a.m. ET in New York City – -- Strong financial position; ending the quarter with $
